<tbody id="jftbj"></tbody>

              INVENTING A NEW

              Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

              Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

              Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

              FOR 30 YEARS, OUR
              MISSION HAS BEEN TO
              USE THE POWER OF
              SCIENCE TO BRING
              NEW MEDICINES TO
              PATIENTS... OVER
              AND OVER AGAIN.

              Neil Stahl, PhD, Executive VP,
              Research and Development

              2018 annual report PDF download

              Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

              Read our annual report
              and responsibility report

              2018 responsibility report PDF download


              • 30
                years of scientific
              • 7,300+
              • 700+
                employees with
                an MD, PhD or
                PharmD degree
              • 6TH
                consecutive year
                in Forbes' World's
                Most Innovative
              • #1
                ranking in Science
                magazine’s global Top
                Employer survey for six
                of the past eight years
              • 31,000+
                employee volunteer hours
                for 100+ organizations
                in 2018
              • 7
              • 94%
                of our waste
                diverted from
                landfill, reaching
                our goal
              • 100%
                of drug candidates
                invented and
                developed in-house
              • 500,000+
                exomes sequenced
                to date
              • 100+
                publications in 2018
              • 20
                product candidates in
                clinical development
                across multiple
                therapeutic areas
              • Shingo Institute: The Shingo Prize, 2019

                Great Places to Work: Best Workplace in Ireland, 2019

                Science: #1 Top Employer, 2018

                Forbes: Top 10 Most Innovative Companies, 2018

                Civic 50: Most Community-Minded Companies in the Nation, 2018

                Fortune: Best Companies to Work for, 2018

              • MIT Technology Review: Top 10 Smartest Companies, 2017

                Fortune: Future 50, 2017

                Barron’s: World’s Best CEOs, 2016

                Scrip Award: R&D Team of the Year, 2016

                Crain’s New York Business: Fast 50, 2015


              We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

              Our leadership

              A FOCUS
              ON SCIENCE

              From our first days, science has remained our central guiding principle.

              Our journey